Research
Older adults hospitalised for heart failure had high risk of kidney complications, finds study

In a study of Medicare beneficiaries, researchers from Brigham and Women’s Hospital found that one year after hospitalisation for heart failure, six per cent of patients had progressed to dialysis.
Researchers from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, have found links between heart failure and kidney disease that support new approaches for integrating the care of these conditions.
In an analysis that included adults ages 65 and older who were hospitalised for heart failure from across 372 sites in the US, researchers found that patients had a substantial risk of kidney complications, with approximately six per cent progressing to dialysis within a year of being hospitalised for heart failure. The new results are published in JAMA Cardiology.
“We know that heart and kidney health are highly interconnected, but management of heart and kidney disease remains relatively siloed, and kidney health often isn’t prioritised in patients with heart disease until advanced stages,” said first author John Ostrominski, MD, a fellow in Cardiovascular Medicine and Obesity Medicine at the Brigham.
“Declining kidney function is often asymptomatic until late in the disease course, but even less advanced stages of kidney impairment can have important implications for cardiovascular health. Hence, there’s a need for analyses that assess kidney outcomes in people with heart failure.”
About two thirds of older adults with heart failure have abnormal kidney function. However, few analyses to date have investigated the occurrence of clinically relevant kidney outcomes, such as hospitalisation for acute kidney injury or dialysis, in patients with heart failure.
Evaluating these more recognisable and patient-centered outcomes, according to Ostrominski, may result in substantial changes to the way that heart and kidney disease are managed together in the clinic.
The study analysed Medicare claims data from 85,298 patients over the age of 65 who were hospitalised with heart failure between 2021 and 2024. The data was sourced from the Get with the Guidelines-Heart-Failure Registry, an initiative supported by the American Heart Association that seeks to connect hospitals with current evidence-based guidelines and accurate measurement tools to improve care quality and industry practices. The registry is also proving a valuable source of information for researchers examining trends in health outcomes for patients with heart failure.
In the present study, 63 percent of patients were discharged with significantly impaired kidney function, as measured by their rate of filtration. The researchers also found that the risk of adverse kidney outcomes increased steeply in patients with lower kidney function. By one year after discharge, six per cent of patients were on dialysis, and seven per cent of patients were either on dialysis or had progressed to end stage kidney disease.
The findings suggest that at the individual provider level, cardiologists should prioritise assessing kidney function – including measuring kidney filtration and looking for evidence of protein in the urine, also known as albuminuria – in all patients with heart failure, and, when indicated, consider heart therapies that are known to improve kidney outcomes.
More broadly, the study emphasises the need for systemic changes that better support the simultaneous management of heart and kidney disease, including establishing clinics focused on integrating these two care areas, incorporating kidney outcomes into health care performance metrics for cardiovascular diseases, and expanding Medicare reimbursement protocols for interdisciplinary chronic care management.
Researchers at Mass General Brigham are actively engaged as sites for clinical trials evaluating newer treatment strategies for individuals with cardiovascular and kidney disease. The Accelerator for Clinical Transformation team is also developing new ways of delivering care—including medications with established kidney benefits—to eligible patients with and without heart failure.
“The trends we’ve observed aren’t especially surprising given what we know about the links between heart and kidney health, but what’s important is that this research emphasises the scope of the problem and gives us information we can act upon to directly improve clinical outcomes in patients with heart failure,” said Ostrominski.
“There are important opportunities for patients and providers, healthcare institutions, and, at the broader state and national levels, in terms of healthcare policy that could make a big difference for patients.”
Research
Just 30 mins of light activity can boost energy and mood, study finds

Swapping just 30 minutes of sitting for light activity, such as walking or housework, can improve mood and energy the following day, new research suggests.
A study involving more than 350 young adults found that on days when participants spent less time sitting and more time doing light activity, they felt happier and more energised the next day.
Researchers said light activity had the strongest link to improved next-day mood, while time spent sitting or lying awake was associated with poorer mood the following day.
The study, led by the University of Texas at Arlington and Monash University in Australia, tracked participants’ 24-hour movement patterns using wearable monitors.
“This study indicated that light activity — where you don’t have to go to the gym or do intense exercise — can lead to better feelings the next day when it replaces sedentary behaviour,” said Dr Yue Liao, kinesiology professor at UT Arlington.
“One doesn’t have to think, ‘I have to run,’ or ‘I have to do these big things.’ Just sitting less and moving more can have an immediate impact on your mood the next day.”
The findings are particularly relevant as 38 per cent of US adults spend nine or more hours sitting each day, according to a 2024 study by smart seating company Kalogon.
Researchers analysed daily activity across sleep, exercise, sedentary time and light movement. Moderate to vigorous activity, such as running or gym workouts, offered smaller mood benefits, while sleep duration showed no clear effect on next-day mood among participants.
“We looked at the 24-hour movement behaviour — sleep, exercise, sedentary time and light activity,” said Dr Liao.
“The 24-hour part is important because we’re not simply saying, ‘Do more of this.’ All these activities add up to 24 hours. From that perspective, when someone replaces sitting time with light activity, it predicts a better mood the next day. That’s the key point.”
The improvements were based on individual changes rather than comparisons between participants.
“Based on previous research, we assumed exercise would be the main factor, but our analysis mostly highlighted light activity,” Dr Liao said.
“You don’t have to work up a sweat to get benefits. Just moving a little more than your usual helps.”
The study suggests that small, everyday adjustments — such as standing up more often or walking briefly — can make a noticeable difference to wellbeing, the researchers concluded.
News
Night-time light exposure may increase stroke and heart attack risk

Bright light at night raises the risk of heart attack by 47 per cent and heart failure by 56 per cent, according to research involving nearly 89,000 people.
Being exposed to bright light at night could significantly increase the chances of developing serious heart problems, including heart attacks, strokes and heart failure.
The largest study of its kind tracked over 13 million hours of light exposure using wrist-worn sensors and followed participants for up to 9.5 years.
Those exposed to the brightest light at night were 56 per cent more likely to develop heart failure and 47 per cent more likely to suffer a heart attack. These risks remained high even after accounting for factors such as exercise, diet, sleep habits and genetics.
Researchers from Flinders University’s FHMRI Sleep Health analysed data from almost 89,000 people in the UK to investigate how personal light exposure affects heart health.
Dr Daniel Windred, lead author and research associate at Flinders University’s FHMRI Sleep Health, said the study highlights a risk factor many people overlook — one that is simple to address.
“This is the first large-scale study to show that simply being exposed to light at night is a strong and independent risk factor for heart disease,” said Dr Windred.
“Disrupting your body’s internal circadian clock by repeatedly exposing yourself to bright light at night, when it would typically be dark otherwise, will put you at a higher risk of developing dangerous heart issues.
“Thankfully, we do have some control over our exposure to light at night.
“By using blackout curtains, dimming lights, and avoiding screens before bed, we can help to reduce the health risks associated with light at night.”
The study also found that women and younger people were especially vulnerable to the effects of light exposure at night.
“Women may be more sensitive to the effects of light disrupting their body clock, which supports earlier research findings,” said senior co-author Professor Sean Cain.
“In fact, women exposed to high levels of night light had similar heart failure risks to men, which is unusual because women typically have some natural protection against heart disease.”
Everyday behaviours may also pose risks, added senior co-author Associate Professor Andrew Phillips.
“Everyday habits, like scrolling on your phone in bed or falling asleep with the TV on or bedroom lights on, can expose you to potentially harmful levels of light,” said Associate Professor Phillips from FHMRI Sleep Health.
“We’re not talking about extreme cases — even low levels of indoor light can interfere with your body’s natural rhythm.”
Unlike previous studies that relied on satellite images or surveys of outdoor light at night, this research used real-time data from wearable devices, providing a clearer picture of how indoor light environments affect health.
The circadian clock — the body’s internal timing system — regulates sleep-wake cycles and other biological processes over about 24 hours.
With heart disease still the leading cause of death worldwide, the researchers say it is time to treat light at night as a health risk, alongside poor diet, lack of exercise and smoking.
The team is calling for more research into lighting guidelines for homes, hospitals and cities to help reduce night-time light exposure.
“We need to take our body clocks seriously,” said Professor Cain.
“Protecting our natural sleep rhythms could be a powerful way to fight heart disease.”
Wellness
Weight loss drug reduces heart attack and stroke risk regardless of weight loss

Semaglutide reduces the risk of heart attack and stroke by 20 per cent, regardless of weight lost, according to the largest study of 17,604 patients.
The drug, the main ingredient in Wegovy, reduced the risk of major adverse cardiac events — including deaths from heart disease, heart attacks or strokes — by 20 per cent, regardless of the weight patients lost.
The findings suggest the drug may have wider benefits beyond weight loss and should not be restricted only to those with the highest body mass index (BMI).
The study, led by researchers at University College London, examined data from 17,604 adults aged 45 and over who were overweight or obese across 41 countries. Half received weekly injections of semaglutide, while the other half were given a placebo.
Previous analysis had already shown semaglutide’s 20 per cent reduction in cardiac events; this follow-up analysis confirmed the benefit remained even when weight loss was minimal.
Even participants who were only mildly overweight — with a BMI of 27, roughly the UK average — saw similar benefits to those with the highest BMI scores.
The benefits were also largely independent of how much weight people lost in the first four months of treatment.
However, a reduction in waist circumference — a measure of abdominal fat — explained about one-third of the observed cardiovascular benefits.
Professor John Deanfield, from UCL’s Institute of Cardiovascular Science, said: “Abdominal fat is more dangerous for our cardiovascular health than overall weight and therefore it is not surprising to see a link between reduction in waist size and cardiovascular benefit.
“However, this still leaves two-thirds of the heart benefits of semaglutide unexplained. These findings reframe what we think this medication is doing.
“It is labelled as a weight-loss jab but its benefits for the heart are not directly related to the amount of weight lost – in fact, it is a drug that directly affects heart disease and other diseases of ageing.”
He added: “This work has implications for how semaglutide is used in clinical practice.
“You don’t have to lose a lot of weight and you don’t need a high BMI to gain cardiovascular benefit. If your aim is to reduce cardiovascular disease, restricting its use to a limited time only and for those with the highest BMIs doesn’t make sense.
“At the same time, the benefits need to be weighed against potential side-effects. Investigations of side-effects become especially important given the broad range of people this medicine and others like it could help.”
The Select trial findings indicate that semaglutide’s cardiovascular effects are likely driven by multiple mechanisms rather than weight loss alone.
While shrinking waistlines contributed to the outcome, most of the heart benefit appears to stem from other biological effects that directly influence cardiovascular pathways.
News1 month agoNHS dementia staff say patients missing out on best care as diagnosis system falls short
News2 weeks agoRoundup: Atlas maps molecular fingerprints of health, disease and ageing
Technology2 months agoQuick test could identify Alzheimer’s risk long before symptoms show
News1 month agoTool could detect early signs of Alzheimer’s
News2 months agoMore children now obese than underweight, UN warns
News3 weeks agoEmotional well-being as important as physical for longevity, study finds
News1 month agoCannabis use quadruples diabetes risk, study finds
News1 week agoFDA greenlights simple Alzheimer’s test






















